Junxiao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Junxiao Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Genhong Cheng
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, USA
12 shared publications - Heng Yang
Chinese Academy of Medical Sciences and Peking Union Medical College 2 National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine Suzhou, China
12 shared publications - Jianfei Huang
Department of Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, P.R. China
12 shared publications - Lili Li
Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China
12 shared publications - Meiling Gao
Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China
12 shared publications - Shumin Hao
Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China
12 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating antitumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tumor tissues also suggested HDAC3 might be involved in antitumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This antitumor mechanism may be helpful in guiding HDAC3 inhibitor–based treatment.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating antitumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tumor tissues also suggested HDAC3 might be involved in antitumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This antitumor mechanism may be helpful in guiding HDAC3 inhibitor–based treatment.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anti-cancer agents, exert their anti-tumor activity by directly causing cell cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating anti-tumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma (HCC) tumor tissues also suggested HDAC3 might be involved in anti-tumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This anti-tumor mechanism may be helpful in guiding HDAC3 inhibitor-based treatment.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anti-cancer agents, exert their anti-tumor activity by directly causing cell cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating anti-tumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma (HCC) tumor tissues also suggested HDAC3 might be involved in anti-tumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This anti-tumor mechanism may be helpful in guiding HDAC3 inhibitor-based treatment.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Supplementary Fig.S1-S9 Table S1-S2
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Supplementary Fig.S1-S9 Table S1-S2
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Supplementary Fig.S1-S9 Table S1-S2
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Supplementary Fig.S1-S9 Table S1-S2
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating antitumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tumor tissues also suggested HDAC3 might be involved in antitumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This antitumor mechanism may be helpful in guiding HDAC3 inhibitor–based treatment.
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating antitumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tumor tissues also suggested HDAC3 might be involved in antitumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This antitumor mechanism may be helpful in guiding HDAC3 inhibitor–based treatment.
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig.S1-S9Table S1-S2
- Open Access
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig. S1-S9 Table S1-S2
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
Supplementary Fig. S1-S9 Table S1-S2